Early access program opens for upadacitinib in Crohn's, colitis, arthritis, and eczema
NCT ID NCT04159597
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program offers early access to upadacitinib (Rinvoq) for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other suitable treatments and cannot join ongoing clinical trials. A doctor must decide if the potential benefits outweigh the risks. The drug is taken as an oral solution.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib (Rinvoq)
What this could lead to
If successful, this program could provide early access to upadacitinib for people with serious inflammatory conditions who have no other good options.
What could go wrong
This is an expanded access program, not a formal trial, so data on safety and effectiveness is limited. Upadacitinib may have side effects, and not everyone will qualify.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••